Pretreatment SUVmax as a Marker for Progression-Free Survival in Stage I NSCLC Treated With SBRT. | Pract Radiat Oncol;3(2 Suppl 1): S3-4, 2013. | MEDLINE

Conteúdo principal 1 Busca 2 Rodapé 3

+A A -A Alto contraste

BVS - MINISTÉRIO DA SAÚDE

Informação e Conhecimento para a Saúde

português

Localizar descritor de assunto Busca Avançada EVID@Easy

Pretreatment SUVmax as a Marker for Progression-Free Survival in Stage I NSCLC Treated With SBRT.

Horne, Z D; Clump, D A; Shah, S; Vargo, J A; Burton, S A; Christie, N A; Schuchert, M J; Landreneau, R J; Luketich, J D; Heron, D E.

Afiliação

Horne ZD; University of Pittsburgh Medical Center, Pittsburgh, PA.
Clump DA; University of Pittsburgh Medical Center, Pittsburgh, PA.
Shah S; University of Pittsburgh Medical Center, Pittsburgh, PA.
Vargo JA; University of Pittsburgh Medical Center, Pittsburgh, PA.
Burton SA; University of Pittsburgh Medical Center, Pittsburgh, PA.
Christie NA; University of Pittsburgh Medical Center, Pittsburgh, PA.
Schuchert MJ; University of Pittsburgh Medical Center, Pittsburgh, PA.
Landreneau RJ; University of Pittsburgh Medical Center, Pittsburgh, PA.
Luketich JD; University of Pittsburgh Medical Center, Pittsburgh, PA.
Heron DE; University of Pittsburgh Medical Center, Pittsburgh, PA.

Pract Radiat Oncol ; 3(2 Suppl 1): S3-4, 2013.

Article em En | MEDLINE | ID: mdl-24674539

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2013 Tipo de documento: Article

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2013 Tipo de documento: Article